IN8bio appoints Kate Rochlin as Chief Operating Officer effective Dec 1, 2021

IN8BIO, INC.

Kate Rochlin, Ph.D. appointed COO; will receive $400,000 base salary and 40% bonus eligibility.
Rochlin previously served as VP, Operations and Innovation at IN8bio since December 2020.
She holds a Ph.D. in Cell and Developmental Biology from Weill Cornell and a B.A. from University of Pennsylvania.
No related-party transactions disclosed with the company.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Kate Rochlin

Chief Operating Officer

INAB · IN8BIO, INC.

Effective: 2021-12-01
Filed: December 9, 2021, 6:59 PM ET

announced that the Board of Directors had appointed Kate Rochlin, Ph.D. as the Company’s Chief Operating Officer, effective as of December 1, 2021.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Kate Rochlin was appointed as Chief Operating Officer at IN8BIO, INC..

Action: appointed
Role: Chief Operating Officer

Exact text from the filing

announced that the Board of Directors had appointed Kate Rochlin, Ph.D. as the Company’s Chief Operating Officer, effective as of December 1, 2021.

View on SEC.gov

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0001193125-21-352727

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.